Completed PHASE2 INTERVENTIONAL 1-arm NCT00423735

Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme

Sponsor: NRG Oncology

Conditions Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma Recurrent Adult Brain Neoplasm

Interventions Dasatinib Pharmacological Study

Updated 12 times since 2017 Last updated: Jul 22, 2019 Started: Jan 24, 2007 Primary completion: Mar 9, 2011 Completion: Sep 4, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Adult Giant Cell Glioblastoma and Adult Glioblastoma and is currently completed. NRG Oncology leads this study, which shows 12 recorded versions since 2007 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2

▶ Show 7 earlier versions

Aug 2019 — Jan 2021 [monthly]

Completed PHASE2
Nov 2018 — Aug 2019 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Aug 2018 — Nov 2018 [monthly]

Active Not Recruiting PHASE2
Jun 2018 — Aug 2018 [monthly]

Active Not Recruiting PHASE2
Mar 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE2
Feb 2017 — Mar 2018 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NRG Oncology
National Cancer Institute (NCI)
Radiation Therapy Oncology Group

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Akron, United States , American Fork, United States , Anderson, United States , Ann Arbor, United States , Auburn, United States , Barberton, United States , Beech Grove, United States , Boca Raton, United States , Boston, United States and 137 more locations